B
BEAM
Beam Therapeutics Inc.
30.47
+0.69+2.32%Pre Market: 30.51 +0.04 +0.13%04:00 06/10 EDT
OPEN/PREV CLOSE30.80/29.78
TODAY RANGE28.99-31.33
VOL55
MARKET CAP3.13B
52 WEEK RANGE15.60-36.44
AVG VOL (3M)2.09M
% TURNOVER1.53%
TURNOVER0
P/E (TTM)-47.4832
% RANGE7.86%
EPS(TTM)-0.6417
P/E(FORWARD)-6.7636
P/B2.688
BVPS11.33
DIVIDEND--
P/S22.19
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP3.09B
SHARES OUTSTANDING102.88M
NEXT EARNINGS08/03-08/07
FREE FLOAT101.48M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·1d ago
Beam Stockholders Back Board, Leadership at Annual Meeting
Seeking Alpha·1d ago
Cathie Wood’s Ark Invest buys tech dip led by NVDA, AVGO, GOOG, META, dumps AMD
Simply Wall St·2d ago
Beam Therapeutics (BEAM) Valuation After Positive BEAM 302 Data And Accelerated FDA Pathway Potential
Seeking Alpha·6d ago
Most and least shorted mid- to mega-cap healthcare stocks at the end of May
Seeking Alpha·06/02 17:50
Draft FDA guidance could be a boon for gene therapy developers
NASDAQ·06/02 16:09
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Simply Wall St·05/30 19:09
A Look At Beam Therapeutics (BEAM) Valuation After Updated BEAM 302 Trial Data And Accelerated Approval Plans
Simply Wall St·05/27 18:06
Why Beam Therapeutics (BEAM) Is Up 13.1% After Pursuing Accelerated Approval For BEAM-302
Simply Wall St·05/26 17:18
Beam Therapeutics Accelerated Approval Bid Puts BEAM-302 At Center Stage
Seeking Alpha·05/21 21:40
These Are The Upcoming Catalysts For Crispr Therapeutics Stock
TipRanks·05/21 11:16
Beam Therapeutics (BEAM) Gets a Buy from Canaccord Genuity
TipRanks·05/21 10:30
Wall Street Analysts Are Bullish on Top Healthcare Picks
Same Industry
Name/Symbol
Change%
Price